Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 109.51% | Wells Fargo | → $1 | Downgrades | Overweight → Equal-Weight |
| 11/03/2023 | 319.02% | RBC Capital | $6 → $2 | Downgrades | Outperform → Sector Perform |
| 08/15/2023 | 1366.58% | Truist Securities | $8 → $7 | Maintains | Buy |
| 08/14/2023 | 947.56% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/11/2023 | 1995.12% | Wedbush | $16 → $10 | Maintains | Outperform |
| 08/10/2023 | 738.05% | Wells Fargo | $5 → $4 | Maintains | Overweight |
| 08/09/2023 | 1785.61% | Barclays | $11 → $9 | Maintains | Overweight |
| 08/09/2023 | 1157.07% | RBC Capital | $8 → $6 | Maintains | Outperform |
| 05/10/2023 | 1576.09% | Truist Securities | $16 → $8 | Maintains | Buy |
| 05/01/2023 | 947.56% | HC Wainwright & Co. | $15 → $5 | Maintains | Buy |
| 04/28/2023 | 214.27% | B of A Securities | $5 → $1.5 | Downgrades | Neutral → Underperform |
| 03/03/2023 | 3042.68% | HC Wainwright & Co. | $25 → $15 | Maintains | Buy |
| 02/27/2023 | 3252.19% | Wedbush | → $16 | Upgrades | Neutral → Outperform |
| 02/23/2023 | 2623.65% | RBC Capital | $22 → $13 | Maintains | Outperform |
| 01/04/2023 | 3042.68% | Wells Fargo | $20 → $15 | Maintains | Overweight |
| 11/07/2022 | 4090.24% | Wells Fargo | $22 → $20 | Maintains | Overweight |
| 06/13/2022 | 947.56% | Wedbush | → $5 | Assumes | → Neutral |
| 04/05/2022 | 3880.72% | Truist Securities | $23 → $19 | Maintains | Buy |
| 05/04/2021 | 4509.26% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 01/06/2021 | 3252.19% | Stifel | → $16 | Initiates Coverage On | → Hold |
| 12/16/2020 | 5137.8% | HC Wainwright & Co. | → $25 | Assumes | → Buy |
| 09/08/2020 | 4090.24% | B of A Securities | → $20 | Reinstates | → Buy |
| 07/07/2020 | 4509.26% | SunTrust Robinson Humphrey | → $22 | Initiates Coverage On | → Buy |
| 06/22/2020 | 2833.17% | HC Wainwright & Co. | $16 → $14 | Maintains | Buy |
| 11/14/2018 | 2204.63% | JP Morgan | $35 → $11 | Maintains | Neutral |
| 11/14/2018 | 2204.63% | JP Morgan | $35 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2018 | — | Guggenheim | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/06/2023 | 109.51% | 富国银行 | → 1 美元 | 降级 | 超重 → 重量相等 |
| 11/03/2023 | 319.02% | 加拿大皇家银行资本 | 6 美元 → 2 美元 | 降级 | 跑赢大盘 → 行业表现 |
| 08/15/2023 | 1366.58% | Truist 证券 | 8 美元 → 7 美元 | 维护 | 买 |
| 08/14/2023 | 947.56% | HC Wainwright & Co. | → 5 美元 | 重申 | 购买 → 购买 |
| 08/11/2023 | 1995.12% | Wedbush | 16 美元 → 10 美元 | 维护 | 跑赢大盘 |
| 08/10/2023 | 738.05% | 富国银行 | 5 美元 → 4 美元 | 维护 | 超重 |
| 08/09/2023 | 1785.61% | 巴克莱 | 11 美元 → 9 美元 | 维护 | 超重 |
| 08/09/2023 | 1157.07% | 加拿大皇家银行资本 | 8 美元 → 6 美元 | 维护 | 跑赢大盘 |
| 05/10/2023 | 1576.09% | Truist 证券 | 16 美元 → 8 美元 | 维护 | 买 |
| 05/01/2023 | 947.56% | HC Wainwright & Co. | 15 美元 → 5 美元 | 维护 | 买 |
| 04/28/2023 | 214.27% | B of A 类证券 | 5 美元 → 1.5 美元 | 降级 | 中性 → 跑赢大盘 |
| 03/03/2023 | 3042.68% | HC Wainwright & Co. | 25 美元 → 15 美元 | 维护 | 买 |
| 02/27/2023 | 3252.19% | Wedbush | → 16 美元 | 升级 | 中性 → 跑赢大盘 |
| 02/23/2023 | 2623.65% | 加拿大皇家银行资本 | 22 美元 → 13 美元 | 维护 | 跑赢大盘 |
| 2023 年 4 月 1 日 | 3042.68% | 富国银行 | 20 美元 → 15 美元 | 维护 | 超重 |
| 2022 年 7 月 11 日 | 4090.24% | 富国银行 | 22 美元 → 20 美元 | 维护 | 超重 |
| 06/13/2022 | 947.56% | Wedbush | → 5 美元 | 假设 | → 中立 |
| 2022 年 5 月 4 日 | 3880.72% | Truist 证券 | 23 美元 → 19 美元 | 维护 | 买 |
| 2021 年 4 月 5 日 | 4509.26% | 加拿大皇家银行资本 | → 22 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 01/06/2021 | 3252.19% | Stifel | → 16 美元 | 启动覆盖范围开启 | → 按住 |
| 2020 年 12 月 16 日 | 5137.8% | HC Wainwright & Co. | → 25 美元 | 假设 | → 购买 |
| 2020 年 8 月 9 日 | 4090.24% | B of A 类证券 | → 20 美元 | 恢复 | → 购买 |
| 07/07/2020 | 4509.26% | SunTrust 罗宾逊·汉弗莱 | → 22 美元 | 启动覆盖范围开启 | → 购买 |
| 06/22/2020 | 2833.17% | HC Wainwright & Co. | 16 美元 → 14 美元 | 维护 | 买 |
| 11/14/2018 | 2204.63% | 摩根大通 | 35 美元 → 11 美元 | 维护 | 中立 |
| 11/14/2018 | 2204.63% | 摩根大通 | 35 美元 → 11 美元 | 降级 | 超重 → 中性 |
| 11/09/2018 | — | 古根海姆 | 降级 | 买入 → 中性 |
What is the target price for Sangamo Therapeutics (SGMO)?
Sangamo Therapeutics（SGMO）的目标价格是多少？
The latest price target for Sangamo Therapeutics (NASDAQ: SGMO) was reported by Wells Fargo on November 6, 2023. The analyst firm set a price target for $1.00 expecting SGMO to rise to within 12 months (a possible 109.51% upside). 16 analyst firms have reported ratings in the last year.
富国银行于2023年11月6日公布了Sangamo Therapeutics（纳斯达克股票代码：SGMO）的最新目标股价。该分析公司将目标股价定为1.00美元，预计SGMO将在12个月内升至12个月内（可能上涨109.51％）。去年有16家分析公司公布了评级。
What is the most recent analyst rating for Sangamo Therapeutics (SGMO)?
分析师对Sangamo Therapeutics（SGMO）的最新评级是多少？
The latest analyst rating for Sangamo Therapeutics (NASDAQ: SGMO) was provided by Wells Fargo, and Sangamo Therapeutics downgraded their equal-weight rating.
富国银行对Sangamo Therapeutics（纳斯达克股票代码：SGMO）的最新分析师评级由富国银行提供，Sangamo Therapeutics下调了其同等权重评级。
When is the next analyst rating going to be posted or updated for Sangamo Therapeutics (SGMO)?
Sangamo Therapeutics（SGMO）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Sangamo Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Sangamo Therapeutics的最新评级是在2023年11月6日公布的，因此您应该预计下一个评级将在2024年11月6日左右公布。
Is the Analyst Rating Sangamo Therapeutics (SGMO) correct?
分析师对 Sangamo Therapeutics (SGMO) 的评级正确吗？
While ratings are subjective and will change, the latest Sangamo Therapeutics (SGMO) rating was a downgraded with a price target of $0.00 to $1.00. The current price Sangamo Therapeutics (SGMO) is trading at is $0.48, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Sangamo Therapeutics（SGMO）评级已下调，目标股价为0.00美元至1.00美元。Sangamo Therapeutics（SGMO）目前的交易价格为0.48美元，在分析师的预测区间内。